June marks Alzheimer’s & Brain Awareness Month. Did you know that the risk of developing Alzheimer’s disease may be influenced by your genes? People who are APOE4 homozygous, meaning they have two copies of a gene variant called APOE4, are approximately 15 times more likely to develop Alzheimer’s. Lexeo is developing CNS-focused gene therapies to address the underlying genetic cause of APOE4-associated Alzheimer’s disease. Learn more about our programs here: https://lnkd.in/g2BGvuSM #ENDALZ #ALZScience
Lexeo Therapeutics’ Post
More Relevant Posts
-
Introducing our Leigh syndrome symposium speaker, Dr. Qinglan Ling. The talk will give a broad overview of the past and future efforts on developing gene therapies for different mitochondrial diseases. Please register: https://lnkd.in/eMmX6ryB #leighsyndrome #mitochondrialdisease
-
-
📣 New publication from Team Liddle! The team developed an optimized #protocol of DSS-induced colitis to test the hypothesis that gut inflammation triggers brain inflammation and disrupts gene networks involved in #brainhealth. https://bit.ly/3TyPlyq
-
STEALTH LONGEVITY Every week I publish an article on under-cover research to extend human healthy lifespan This week I explore mono and combinatorial gene therapies to treat aging and age-related diseases. The most surprising fact for me is the sheer amount of research coming out of China in this specific field https://lnkd.in/dYy4Wbk7
-
We are seeing the results of years of clinical research on CRISPR coming to fruition to provide a long needed therapeutic for sickle cell disease. Few know that CRISPR technology is being used to treat many diseases like cancer and HIV. Now we need community advocacy to ensure it is accessible and affordable. #clinicaltrials #sicklecelldisease #CRISPR #healthequity #patientadvocacy #AfricanAmericans
ICYMI: The FDA approved two gene therapies for the treatment of sickle cell disease in patients 12 years and older. Read a joint statement from NHLBI (https://go.nih.gov/2GJt2BF) and the National Human Genome Research Institute (NHGRI) https://go.nih.gov/1ZOhVi4.
-
-
Breaking news in the world of hematology! 🩸 New research reveals that individuals with severe sickle cell disease have shown a remarkable tolerance for gene therapies. Learn more about this exciting development that could bring hope and relief to those battling this challenging condition. 💪 Read the full article here: https://lnkd.in/ggJafAVj #GeneTherapy #HematologyAdvances #HealthcareInnovation
-
-
Helping people build resiliency, while enhancing their individual and collective well-being.
Breaking news in the world of hematology! 🩸 New research reveals that individuals with severe sickle cell disease have shown a remarkable tolerance for gene therapies. Learn more about this exciting development that could bring hope and relief to those battling this challenging condition. 💪 Read the full article here: https://lnkd.in/evRH6XBk #GeneTherapy #HematologyAdvances #HealthcareInnovation
-
-
The Cell and Gene Therapy Catapult featured in a supplement in The Guardian today for Rare Disease Day 2024, with our Chief Executive, Matthew Durdy, discussing the current pioneering #cell and #gene therapies for rare diseases and the potential to offer treatments for more common conditions in the future. Learn more: https://buff.ly/3uJ4u6K #CellTherapy #GeneTherapy #ATMPs #AdvancedTherapies #RareDiseases24
-
-
Gaucher disease is a rare inherited (genetic) enzyme deficiency disorder. One of the ways forward in the treatment of Gaucher disease is gene therapy. For Type 1 Gaucher disease, there are a number of gene therapy clinical trials currently looking for participants to enrol. The IGA has compiled information about these trials on a dedicated web page with the aim of making it easy for the community to understand the similarities and differences between them. Visit tiny.cc/gttrials to learn more. #tuesdaytakeover #RareDisease #RareDiseaseCharity #PatientAdvocacy #PatientVoice #PatientEngagement #Gaucher #GaucherDisease #EnzymeDecifiencyDisorder #GeneTherapy #RareDiseaseDay2024 #RareDiseaseDay #RDD2024 #RDD
-
-
We have been featured at European Biopharmaceutical Review (EBR), Samedan Ltd (pages 14-16) on how our technologies are shaping the next era of bioprocessing. If you want to participate on this mission, send us a message and let's build a success story together. European Biopharmaceutical Review, Winter 2024, pages 14-16. © Samedan Ltd #CULTZYME #Biology #Personalisedmedicines #Intelligentbioprocessing
Our Winter issue is now out! Our first issue of 2024 covers cell and gene therapies, degenerative diseases, drug discovery and development, and more! 💊 👩🔬 Check it out at the link below: bit.ly/3u4bPNI
-
-
Centralisation of information and decentralisation of operation are key factors that will advance the synthetic biology ecosystem in all its verticals. At CULTZYME we are committed to providing a unique tool in its field that will democratise synthetic biology. Check out our recent article European Biopharmaceutical Review (EBR) on how our technologies are shaping the next era of bioprocessing. #CULTZYME #intelligentbioprocessing
Our Winter issue is now out! Our first issue of 2024 covers cell and gene therapies, degenerative diseases, drug discovery and development, and more! 💊 👩🔬 Check it out at the link below: bit.ly/3u4bPNI
-
